Symphogen A/S
As of the edition of 20 October 2026, Symphogen A/S runs 9 drugs; it is on route A at 5 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Symphogen A/S was acquired.
- Symphogen A/S: acquired
Drugs by status
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 2 |
| Stopped | 3 |
| Status not established | 3 |
| Total | 9 |
Where it needs a new molecule
Route A at 5 targets, route B at 0 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Symphogen A/S needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 15 trials led
- Digestive system: 8 trials led
- Blood and lymph: 4 trials led